Iminostilbene

Iminostilbene (CAS No.: 256-96-2) is a synthetic small molecule of the dibenzazepine scaffold that is primarily categorized as a bioactive research intermediate and pharmacological probe in inflammation and metabolic signaling studies, with additional relevance as a precursor framework in medicinal chemistry programs; within biomedical research settings, it has been investigated for inhibitory activity toward PKM2 and COX2 and for modulation of the PKM2 associated HIF 1 alpha and STAT3 signaling axis, leading in experimental systems to reduced expression of pro inflammatory mediators such as COX2 and iNOS and attenuation of stimulus induced cytokine and chemokine release including IL 1 beta, IL 6, TNF alpha, and MCP 1 in macrophage centered models, thereby supporting its use in mechanistic studies of innate immune activation, immunometabolic reprogramming, and tissue injury related inflammatory responses; reported bioactivity is generally described at nanomolar to micromolar range depending on assay context, target system, and endpoint selection, and current evidence is most suitable for preclinical discovery workflows such as target validation, pathway interrogation, hit to lead profiling, and efficacy benchmarking in cell based inflammation models and animal models of inflammatory stress including myocardial ischemia reperfusion related injury, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, while all use remains restricted to laboratory research and not to human consumption or any clinical application.